Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19
F. Lemaı̂tre, Klemens Budde, Teun van Gelder, et al.
Therapeutic Drug Monitoring (2022) Vol. 45, Iss. 2, pp. 191-199
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Acute graft-versus-host disease
Florent Malard, Ernst Holler, Brenda M. Sandmaier, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 104
Should We Transplant Candidates With a Positive SARS-CoV-2 RT-PCR Test?
Iliès Benotmane, Nathan Kasriel, Christophe Masset, et al.
Transplantation (2025)
Closed Access | Times Cited: 1
Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies
Yangming Tang, Yue Li, Turun Song
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Qinqin Zhao, Bei Zheng, Bing Han, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 8, pp. 2087-2102
Open Access | Times Cited: 13
Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19
Lidvine Boland, Arnaud Devresse, Caroline Monchaud, et al.
Transplant International (2024) Vol. 37
Open Access | Times Cited: 5
Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review
Romina Quercia, Giovanni Di Perri, C. Pein, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 5, pp. 1005-1017
Open Access | Times Cited: 5
Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir
Jacqueline Gerhart, Florin Draica, Michael Benigno, et al.
The AAPS Journal (2023) Vol. 25, Iss. 5
Open Access | Times Cited: 12
The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19
Yinhua Gong, Dan Shen, Jinfang Shi, et al.
Journal of International Medical Research (2025) Vol. 53, Iss. 1
Open Access
Comparative Effectiveness of Outpatient COVID‐19 Therapies in Solid Organ Transplant Recipients
Zachary A. Yetmar, Viengneesee Thao, David A. Helfinstine, et al.
Transplant Infectious Disease (2025)
Closed Access
A patent review of CYP3A4 inhibitors (2018 - present)
Dong‐Zhu Tu, Xueyan Hu, J. Lei, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Optimization of the Tacrolimus Concentration-to-Dose Ratio Cut-Off Value to Define Metabolism Groups
Gerold Thölking, Samare P.I. Huls, Katharina Schütte‐Nütgen, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2542-2542
Open Access
Multifunctional Light Emitters for Theranostics
Muyideen Olaitan Bamidele, Micheal Bola Bamikale, Moses Bamidele, et al.
Engineering materials (2025), pp. 297-329
Closed Access
A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database
Min Xu, Shanggang Xu, Xun Yi
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation
Hideo Shiohira, Shingo Arakaki, Wataru Uehara, et al.
Journal of Infection and Chemotherapy (2023) Vol. 30, Iss. 1, pp. 77-80
Closed Access | Times Cited: 9
A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19
Xiujing Zhu, Lin Li, Bing Dai, et al.
International Journal of Analytical Chemistry (2024) Vol. 2024, pp. 1-9
Open Access | Times Cited: 3
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients
Sabina Herrera, José María Aguado, Francisco Javier Candel, et al.
Transplantation Reviews (2023) Vol. 37, Iss. 4, pp. 100788-100788
Closed Access | Times Cited: 8
Tacrolimus—why pharmacokinetics matter in the clinic
Lino Henkel, U. Jehn, Gerold Thölking, et al.
Frontiers in Transplantation (2023) Vol. 2
Open Access | Times Cited: 8
A Case Report of Drug Interactions Between Nirmatrelvir/Ritonavir and Tacrolimus in a Patient With Systemic Lupus Erythematosus
Nanae Yamamoto, Yuichi Tsuchiya, Mio Fukuda, et al.
Cureus (2024)
Open Access | Times Cited: 2
Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation: A case report
Hayato Akamatsu, Yusuke Kohno, Junya Hashizume, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 9, pp. 928-933
Closed Access | Times Cited: 2
Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing Regimen Selection in Clinical Practice
Ping Yang, Wei Liu, Yingqiu Ying, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 2, pp. 107199-107199
Closed Access | Times Cited: 2
A model-based pharmacokinetic assessment of drug–drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19
Takeshi Tomida, Kotaro Itohara, Kazuhiro Yamamoto, et al.
Drug Metabolism and Pharmacokinetics (2023) Vol. 53, pp. 100529-100529
Closed Access | Times Cited: 6
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
Angioletta Lasagna, Irene Cassaniti, Daniele Lilleri, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 9
Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
Yixian Li, Yong Liu, Luping Wen, et al.
Frontiers in Pediatrics (2023) Vol. 11
Open Access | Times Cited: 5
Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)
Marc Hilhorst, Fréderike J. Bemelman, Annette Bruchfeld, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 8, pp. 1807-1816
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top